ClinicalTrials.gg
RecruitingNCT07207291Updated Oct 3, 2025

Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers

A Phase 1 interventional study of JKN2501 and Placebo in Bacterial Infections, Urinary Tract Infections and Intra-Abdominal Infections, sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies in Bacterial Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. Bacterial Infections · China.

Planned enrollment
13th of 16
66 · median 259
Started
2025
with 2 others
Phase 1
5 of 32
3 open now
Registered
29th of 32
by date

Among the 32 studies in Bacterial Infections with a site in China, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 29th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 85 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

10 of the 32 studies in Bacterial Infections with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Bacterial Infections with a site in China, or all of them as a file.
02

Study summary

This Phase I study is a randomized, double-blind, placebo-controlled, dose-escalation trial conducted at a single center. It consists of two parts:

Part 1 (SAD): Evaluates the safety, tolerability, and pharmacokinetics (PK) of single ascending intravenous doses of JKN2501 in healthy adults. Biological samples (blood, urine, feces) will be collected for PK analysis.

Part 2 (MAD): Evaluates the safety, tolerability, and PK of multiple ascending intravenous doses of JKN2501 in healthy adults.

Dose levels may be adjusted based on emerging safety, tolerability, and PK data from preceding cohorts.

03

Conditions studied

  • Bacterial Infections
  • Urinary Tract Infections
  • Intra-Abdominal Infections
  • Respiratory Tract Infections

Keywords

  • Bacterial Infections
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary ; able to comply with study requirements and communicate effectively.
  • Healthy subjects aged 18-45 years (inclusive) at screening.
  • 19.0-26.0 kg/m² (inclusive); weight ≥50 kg (male) or ≥45 kg (female).
  • Vital signs, physical examination, , laboratory tests, chest X-ray, and abdominal ultrasound results judged as normal or clinically insignificant by the investigator.
  • Agreement to use effective non-pharmaceutical from signing ICF until 90 days after last dose; no sperm/egg donation plans during this period.

Exclusion criteria

Exclusion Criteria:

  • Pregnant/lactating women; positive pregnancy test; unprotected sex within 2 weeks prior to dosing.
  • Investigator-determined history or presence of disorder that may affect safety or trial participation.
  • Use of drugs known to inhibit/induce hepatic metabolism within 4 weeks, or any medication (prescription, OTC, herbal, vitamins) within 2 weeks prior to dosing; planned use during the trial.
  • Major surgery within 3 months prior to screening or planned during trial; history of surgery potentially affecting results.
  • History of febrile illness or active infection within 2 weeks prior to screening.
  • Blood loss/donation >400 mL within 3 months prior to screening, or received blood products; plans to donate blood during trial or within 30 days after last dose.
  • History of significant food/drug allergy, or allergy to JKN2501/.
  • Excessive alcohol consumption; inability to abstain from alcohol from 48h pre-dose until end of study.
  • Smoking ≥5 cigarettes/day within 3 months prior to screening; inability to abstain from smoking from 48h pre-dose until end of study.
  • History of drug abuse; positive urine drug screen at baseline (Day -1).
  • Positive alcohol breath test at baseline (Day -1).
  • Participation in another interventional clinical trial within 3 months prior to screening or planned during this trial.
  • Estimated (eGFR) \<90 mL/min.
  • Serum total calcium below lower limit of normal at screening.
  • Investigator-determined unsuitable venous access for PK sampling/infusion, or history of adverse symptoms/phobias related to infusion/phlebotomy.
  • Excessive daily intake of tea, coffee, or caffeinated beverages within 3 months prior to screening.
  • Consumption of grapefruit, Seville oranges, caffeine, or xanthine-rich foods/beverages within 48h prior to first dose; inability to abstain during the trial.
  • History of prolongation; or investigator-determined clinically significant abnormalities at screening/baseline.
  • Any other condition deemed by the investigator to make the subject unsuitable for participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    SAD Cohort1

    JKN2501 125mg only, without placebo.

    Drug: JKN2501

  • Experimental
    SAD Cohort2

    JKN2501 B mg

    Drug: JKN2501 · Drug: Placebo

  • Experimental
    SAD Cohort3

    JKN2501 C mg

    Drug: JKN2501 · Drug: Placebo

  • Experimental
    SAD Cohort4

    JKN2501 D mg

    Drug: JKN2501 · Drug: Placebo

  • Experimental
    SAD Cohort5

    JKN2501 E mg

    Drug: JKN2501 · Drug: Placebo

  • Experimental
    MAD Cohort1

    JKN2501 F mg

    Drug: JKN2501 · Drug: Placebo

  • Experimental
    MAD Cohort2

    JKN2501 G mg

    Drug: JKN2501 · Drug: Placebo

  • Experimental
    MAD Cohort3

    JKN2501 H mg

    Drug: JKN2501 · Drug: Placebo

Interventions

  • DrugJKN2501

    Administration: Intravenous (IV) infusion.

  • DrugPlacebo

    0.9% Sodium Chloride Injection as Placebo. Administration: Intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of single and multiple intravenous (IV) infusions of JKN2501 for Injection in healthy adults.

    Number of participants with treatment-related adverse events as assessed by CTCAE V5.0. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.

Secondary outcomes

  1. Pharmacokinetic parameter of JKN2501: Tmax

    Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.

  2. Pharmacokinetic parameter of JKN2501: Cmax

    Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.

  3. Pharmacokinetic parameter of JKN2501: t1/2

    Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.

  4. Pharmacokinetic parameter of JKN2501: AUC0-t

    Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.

  5. Pharmacokinetic parameter of JKN2501: AUC0-∞

    Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.

  6. Pharmacokinetic parameter of JKN2501: CL

    Time frame: SAD: Baseline to Day 8 post-dose. MAD: Baseline to Day 18 post-dose.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2026, 6 months after the start.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 6 months is below that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Oct 3, 2025
StartActual
Aug 22, 2025
Primary completionEst.
Mar 19, 2026
CompletionEst.
Mar 19, 2026
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07207291
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Aug 22, 2025
Primary completion
Mar 19, 2026 (estimated)
Completion
Mar 19, 2026 (estimated)
Last update
Oct 3, 2025

Study contacts

Yin Yang
Contact
overseas@joincare.com
+86-0755-33268688

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion